Putting More Weight on Obesity Trials in Heart Failure.
Curr Heart Fail Rep
; 21(3): 194-202, 2024 06.
Article
en En
| MEDLINE
| ID: mdl-38619690
ABSTRACT
PURPOSE OF REVIEW To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. RECENT FINDINGS:
Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Pérdida de Peso
/
Insuficiencia Cardíaca
/
Obesidad
Límite:
Humans
Idioma:
En
Revista:
Curr Heart Fail Rep
Asunto de la revista:
CARDIOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos